SUBA® bioavailability technology.

Enhancing the bioavailability of poorly soluble drugsEnhancing the bioavailability of poorly soluble drugs

SUBA technology is a novel technology for enhancing the bioavailability of poorly soluble drugs. The technology utilizes a solid dispersion of drug in a polymer that improves the dissolution of poorly soluble drugs compared to their normal crystalline form. This results in an improvement of the absorption in the gastrointestinal tract to achieve “super bioavailability” compared to conventional formulations.

SUBA technology has been successfully applied to improve the bioavailability of the poorly soluble anti-fungal drug itraconazole which has variable pharmacokinetics. SUBA-Itraconazole and has received regulatory approval in the US, Australia and a number of European and South American markets. The brand name is TOLSURA® in the US and LOZANOC® in Australia.

Potential benefits of SUBA technology include:

  • Increased bioavailability
  • Reduced intra/inter-patient variability in pharmacokinetics

How may we help you?

Fill out the form below or call us on +61 8 8209 2453 to discuss your pharmaceutical project needs.

Please note no enquiries for job applications are accepted via this form. Please see here for the current job opportunities available at Mayne Pharma.